ALUPENT
LOE ApproachingNDAORALSYRUP
Approved
May 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is an oral syrup small-molecule bronchodilator approved in 1975 by Boehringer Ingelheim. The drug's specific mechanism of action and therapeutic indications are not fully documented in available data. It is a legacy product in the respiratory/bronchodilator category.
LOE Approaching
Product is approaching loss of exclusivity with low competitive pressure (30%), suggesting a contracting team focused on managed decline and cost optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ALUPENT offers limited growth prospects as the product approaches loss of exclusivity with zero linked job openings. Roles focus on defending market share, managing pricing erosion, and transition planning rather than expansion.
Field SalesBrand Manager
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.